|
|
Home > Healthcare > Pharmaceutical > General Pharmaceutical
Algeria Pharmaceuticals and Healthcare Report Q4 2008
|
|
Algeria remains a key market in Africa, despite dropping to equal 12th place with Nigeria. It is thesecond-largest African country by territory, and is modernising its healthcare system through oil and gasrevenues, which have risen considerably in recent years. Despite this increase in revenues the standard ofhealthcare provision across the country is uneven.
The main attractions of the Algerian market are it’s relatively large and young population (Algeria’spopulation is in excess of 34mn), its high dependence on imported medicines and steady forecast growthare key attractions.
BMI forecasts that the value of the Algerian market will be US$5.39bn. Generics will continue torepresent the bulk of consumption in terms of volumes. This is especially likely since the Ministry ofHealth and Population has implemented measures that mean that as a condition of receiving an importlicence, medicine importers must pledge that 45% of their imports will be generics. However, with aimsfor World Trade Organisation (WTO) accession, it is likely that conditions for multinationals willimprove and gradually result in the further erosion of their market value share by patented drugs.
Algeria was been included in BMI’s Business Environment Ranking table for Q308 for the first time. Itshares 12th place with Nigeria. Algeria is found above other African markets in the table, namely Kenyaand Zimbabwe; however, it is far behind the continent’s most developed market South Africa. Algeria’sscore for risks to potential returns is negatively impacted by the government’s strong pro-generics stanceand shortcomings of the country’s intellectual property rights (IPR) regime. The country’s excessive redtape and corruption are also viewed with concern, as are certain macroeconomic indicators. On a positivenote, the forecast pharmaceutical value growth and rising numbers of urban dwellers are factors in favourof local investment, as is the fact that the country is making progress towards WTO membership.
Pharmaceutical market growth over the next five years will be stimulated by the continuation of theUS$2bn healthcare modernisation 2005-2009 programme, which envisages the building of numeroushospitals and clinics. Authorities are aiming to improve healthcare access. Adequate provision of healthservices is a challenging proposition, given the vast inhospitable areas of the country. The World Bankhas warned that projects should be implemented gradually and that the government should return to theviable level of spending for the longer term.
Illustrating the above situation, local press in October 2007 revealed that French pharmaceutical majorSanofi-Aventis is considering creating a local manufacturing facility in Algeria, which would be engagedin the production of generic medicines.
|
Similar Products
• Kuwait Pharmaceuticals and Healthcare Report Q4 2008
Published Dec 2008 by Business Monitor International
• France Pharmaceuticals and Healthcare Report Q4 2008
Published Dec 2008 by Business Monitor International
• Kenya Pharmaceuticals and Healthcare Report Q4 2008
Published Dec 2008 by Business Monitor International
• Bangladesh Pharmaceuticals and Healthcare Report Q4 2008
Published Dec 2008 by Business Monitor International
• India Pharmaceuticals and Healthcare Report Q4 2008
Published Dec 2008 by Business Monitor International
• Study for Opportunities Assessment for Hepatitis B Therapeutics in Taiwan
Published Dec 2008 by Frost & Sullivan
• New Types of HIV Drugs
Published Dec 2008 by Trimark Publications
• Diabetes Death Rate by Race and Sex in the U.S., 1979-2006
Published Dec 2008 by Trimark Publications
• Hypertension Drugs Newly Prescribed or Continued in the U.S., 1994-2007
Published Dec 2008 by Trimark Publications
• Infant Mortality Rate by Country, 2008
Published Dec 2008 by Trimark Publications
|
|
|
|
0 items
